Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99

BACKGROUND: The HER2 extracellular domain shed in blood (HER2(ECD)) is reported to rise and fall in parallel with HER2+ breast cancer behavior. In this study, we evaluated the clinical relevance of plasma HER2(ECD) values in patients with metastatic breast cancer treated in the SAKK22/99 trial compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Eppenberger-Castori, Serenella, Klingbiel, Dirk, Ruhstaller, Thomas, Dietrich, Daniel, Rufle, Daniel Alexander, Rothgiesser, Karin, Pagani, Olivia, Thürlimann, Beat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014942/
https://www.ncbi.nlm.nih.gov/pubmed/32046665
http://dx.doi.org/10.1186/s12885-020-6594-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014942/
https://www.ncbi.nlm.nih.gov/pubmed/32046665
http://dx.doi.org/10.1186/s12885-020-6594-0

Ejemplares similares